Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology

NEW YORK–(BUSINESS
WIRE)–Intellicell Biosciences, Inc.;
(“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary,
patent, pending technology for the manufacture of stromal vascular fraction
from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in
Sydney, Australia. The license calls for a one-time payment of $700,000 and a
royalty stream of 12 ½ % of net of sales.

Intellicells process is a patent-pending non-enzymatic
method for deriving stromal vascular fraction from 60ccs of adipose tissue.
This process dramatically increases the yield in manufacturing stromal vascular
fraction compared to the present enzymatic methods in use today. Intellicells
process generates between half billion – 1.4 billion SVFC cells from 60 ccs
from a patients own adipose tissue. This is approximately 10-20 times greater
than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely
excited about our licensing partnership with Cell-Innovations, Inc. We believe
they are one of the best positioned companies to market the Intellicell
technology in Australia & New Zealand.

Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine
market by providing innovative IntelliCell technology to the Australian and New Zealand
marketplace. We believe that IntelliCell technology will be a “game-changer” in
the regenerative medicine field making available stromal vascular fraction
(SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD
a founder of Australian Cell Technologies, a company introducing regenerative
cellular products to the veterinary market. Dr. Thomas has 25 years experience
in cell biology and developed kits for adipose SVF for the veterinary market.
Dr. Thomas research contributions has been recognized by many publications and
book chapters, and is a reviewer for both national and international granting
bodies and journals; and, will be a scientific advisor for IntelliCell. Dr
Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer
in stromal vascular fraction treatments in Australia, a Fellow and Member of
many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been
treating patients with adipose SVF since 2009 for osteoarthritis and
degenerative neurological disease and is one of the most experienced physicians
in Australia
in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist
Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence where
doctors can treat their patient”

About IntelliCell BioSciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the
expanding regenerative medical markets using stromal vascular fraction derived
from adult adipose tissue. IntelliCell intends to initially focus on selling
laboratory suites and licensing its technology to doctors for use in their
offices for their patients. The company is also setting upCenters of Excellence
where doctors can treat their patients. In addition, IntelliCell BioScience in
exploring storing the stromal vascular fraction in cryostorage for future uses.
The company is also starting FDA
IND clinical trials at major
medical centers for clinical indication approval. IntelliCell intends to pursue
expansion to secondary markets and beyond the U.S. through a combination of
company-owned and licensed clinical facilities. For additional information,
visit http://www.intellicellbiosciences.com or call 212-249-3050.

Posted by Sean Fenske, Editor-in-Chief, MDT